ClinicalTrials.gg
CompletedNCT02550418TOPICAL-1Updated Jul 26, 2017

Budesonide 9 mg Capsules in Active UC

A Phase 2 interventional study of Budesonide in Colitis, Ulcerative, sponsored by Dr. Falk Pharma GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-07-26.

Sponsored by Dr. Falk Pharma GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing budesonide in Colitis, Ulcerative — 1 open to participants now, 1 under way, none of them phase 3. Budesonide · Colitis, Ulcerative.

Enrollment
9th of 10
60 · median 183
Started
2015
the only one that year
Phase 2
2 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Dr. Falk Pharma GmbH

Among the 10 studies testing budesonide in Colitis, Ulcerative, this one is the 9th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 7th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 10 studies testing budesonide in Colitis, Ulcerative is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing budesonide in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ,
  • Men or women aged 18 to 75 years,
  • Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology,
  • Established disease,

Exclusion criteria

Exclusion Criteria:

  • Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis,
  • Toxic megacolon or fulminant colitis,
  • Colon resection,
  • Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile toxin in stool culture at screening),
  • Malabsorption syndromes,
  • Celiac disease,
  • Bleeding hemorrhoids,
  • Active peptic ulcer disease
  • Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,
  • Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,
  • Any severe infectious disease (e.g., tuberculosis, AIDS),
  • Severe co-morbidity substantially reducing ,
  • History of colorectal cancer,
  • History of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Budesonide

    Drug: Budesonide

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of clinical remission at final/withdrawal visit

    Clinical remission includes normalisation of stool frequency and absence of blood in stools

    Time frame: 8 weeks treatment

Secondary outcomes

  1. Rate of endoscopic remission/improvement at final/withdrawal visit

    Time frame: 8 weeks treatment

  2. Number of stools / bloody stools per week

    Time frame: 8 weeks treatment

07

Study locations

1 site
  • University of Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
08

References and documents

Publications

  • Fellermann K, Schiefke I, Racz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). United European Gastroenterol J. 2020 Dec;8(10):1186-1195. doi: 10.1177/2050640620962632. Epub 2020 Oct 7. PubMed 33028169 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2015
First posted
Sep 15, 2015
Start
Oct 2015
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Jul 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02550418
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Oct 2015
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Jul 26, 2017

Study contacts

Klaus Fellermann, MD
principal investigator · University Hospital Schleswig-Holstein

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion